Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Orion Oyj A (ORNAV)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
36.35 -0.25    -0.68%
16:29:40 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 6,385
  • Bid/Ask: 36.35 / 36.35
  • Day's Range: 36.25 - 36.75
Type:  Equity
Market:  Finland
ISIN:  FI0009014369 
S/N:  33232361
Orion Oyj A 36.35 -0.25 -0.68%

Orion Oyj A Company Profile

 
Read the Orion Oyj A company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

3574

Equity Type

ORD

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson’s disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic and proprietary drugs, as well as provides contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. The company serves primarily healthcare services providers and professional, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Further, it has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Additionally, the company has research collaboration and licensing agreement with Glykos Finland Oy to develop next-generation antibody-drug conjugates. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Contact Information

Address Orionintie 1A
Espoo, 02200
Finland
Phone 358 10 4261
Fax -

Top Executives

Name Age Since Title
Ari Tapio Lehtoranta 58 2017 Independent Director
Mikael Silvennoinen 65 2014 Independent Chairman
Eija Ronkainen 55 2016 Independent Director
Kari Jussi Aho 62 2020 Independent Director
Hilpi Rautelin 61 2017 Independent Vice Chairman of the Board
Veli-Matti Johannes Mattila 61 2021 Independent Director
Maziar Mike Doustdar 52 2022 Independent Director
Karen Lykke Sorensen 60 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ORNAV Comments

Write your thoughts about Orion Oyj A
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email